FDA advisory panel set to review Grail’s multi-cancer Galleri screening test

An FDA advisory committee is scheduled to evaluate Grail’s Galleri blood test, which is designed to detect a range of cancers at an early stage.

The panel will examine the test’s clinical data, performance metrics, and any safety or regulatory issues before making a recommendation.

The announcement appears alongside other industry news, including new regulatory guardrails in China’s biotech sector and recent toxicity concerns affecting radiopharma developments.